Stockscreener 앱 받기
13.13
2.38%
-0.32
전일 마감가:
$13.45
열려 있는:
$13.52
하루 거래량:
362.36K
Relative Volume:
0.55
시가총액:
$896.85M
수익:
$568.09M
순이익/손실:
$27.27M
주가수익비율:
40.08
EPS:
0.3276
순현금흐름:
$71.41M
1주 성능:
-4.92%
1개월 성능:
-8.63%
6개월 성능:
+46.38%
1년 성능:
+95.68%
1일 변동 폭
$13.02
$13.52
1주일 범위
$13.02
$14.15
52주 변동 폭
$6.37
$15.89
Bioventus Inc Stock (BVS) Company Profile
명칭
Bioventus Inc
전화
(919) 474-6700
주소
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Compare BVS vs ABT, MDT, SYK, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
13.13 | 943.29M | 568.09M | 27.27M | 71.41M | 0.3276 |
ABT
Abbott Laboratories
|
97.50 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.38 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.43 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
42.60 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.15 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-27 | 개시 | CJS Securities | Market Outperform |
| 2026-02-09 | 개시 | Barrington Research | Outperform |
| 2025-07-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-17 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-12-07 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-08-09 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2022-11-22 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2022-11-09 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2022-11-09 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2022-03-15 | 개시 | Craig Hallum | Buy |
| 2021-11-15 | 재개 | Morgan Stanley | Overweight |
| 2021-11-10 | 재개 | JP Morgan | Overweight |
| 2021-07-01 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-03-08 | 개시 | Canaccord Genuity | Buy |
| 2021-03-08 | 개시 | Goldman | Buy |
| 2021-03-08 | 개시 | JP Morgan | Overweight |
| 2021-03-08 | 개시 | Morgan Stanley | Overweight |
모두보기
Bioventus Inc 주식(BVS)의 최신 뉴스
Bioventus: The Tax Line Steals the Show - Orthopedics This Week
What Bioventus Holders Worked Out That You Can Use Elsewhere - Simply Wall Street
Bioventus: Durolane Growth and Deleveraging Offset Uneven Segment Performance - Kalkine
Bioventus Inc. (NASDAQ:BVS) Stock Now Rated "Moderate Buy" by Wall Street Analysts - MarketBeat
BIOVENTUS INC. (NASDAQ: BVS) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Bioventus Inc. (NASDAQ: BVS) - Lelezard
Bioventus: Cash Flow Anchors The Bull Case Beyond A Potential Sale (NASDAQ:BVS) - Seeking Alpha
Bioventus Stock Price Forecast. Should You Buy BVS? - StockInvest.us
Bioventus Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:BVS) 2026-03-05 - Seeking Alpha
Bioventus Inc. (BVS) Stock Analysis: Exploring a Potential 39% Upside in the Healthcare Sector - DirectorsTalk Interviews
Bioventus Inc (BVS) Shares Fall 4.3% -- What GF Score of 53 Tells Investors - GuruFocus
Bioventus Inc. (BVS) Slides 4.32% to $12.63 as Shares Pull Back Toward Key SupportDefined Outcome ETF - dars.gov.et
Bioventus Inc. (BVS) Edges Higher as Stock Tests Resistance Near $13.86Momentum Surge Alerts - siam.in
Bioventus Inc. Stock Price Prediction: Today, Tomorrow, Next Week (BVS) - Traders Union
Bank of New York Mellon Corp Takes Position in Bioventus Inc. $BVS - MarketBeat
Bioventus (BVS) Retreats 2.90% to $13.23, Testing Key Support ZonePut Call Ratio - dars.gov.et
Liquidity Mapping Around (BVS) Price Events - Stock Traders Daily
Bioventus (NASDAQ:BVS) Gains As Healthcare Demand Supports Growth - Kalkine Media
Bioventus Inc. (NASDAQ:BVS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Bioventus Inc (BVS) Stock Up 5.1% but GF Value Says Overvalued -- GF Score: 58/100 - GuruFocus
Bioventus Inc. Class A (BVS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
BIOVENTUS INC. (BVS) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of The Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Bioventus Inc. (BVS) - TMX Newsfile
Bioventus Inc. (BVS) Holds Steady Near $13.84 as Investors Weigh Support and ResistanceExhaustion Gap - siam.in
Bioventus Inc. Class A (BVS) Peer Comparison – Compare with Others - Value Research
Are Investors Undervaluing Bioventus (BVS) Right Now? - qz.com
Globeflex Capital L P Purchases New Shares in Bioventus Inc. $BVS - marketbeat.com
Are Medical Stocks Lagging Bioventus (BVS) This Year? - Yahoo Finance
After Plunging 22% in 4 Weeks, Here's Why the Trend Might Reverse for Bioventus (BVS) - easternprogress.com
Bioventus (BVS) to Report Q2 Results: Wall Street Expects Earnings Growth - Eastern Progress
Bioventus (BVS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Eastern Progress
Does Bioventus (BVS) Have the Potential to Rally 28.92% as Wall Street Analysts Expect? - Eastern Progress
Can Bioventus (NASDAQ:BVS) Keep Its Momentum Going? - Kalkine Media
BVS Maintains Buy Rating by Canaccord Genuity -- Price Target Ra - GuruFocus
BVS Reiterated by Cantor Fitzgerald -- Price Target Maintained a - GuruFocus
Bioventus (NASDAQ:BVS) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - MarketBeat
CCORF Initiates Bioventus(BVS.US) With Buy Rating, Announces Target Price $19 - Moomoo
Bioventus' (BVS) "Overweight" Rating Reiterated at Cantor Fitzgerald - MarketBeat
(BVS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Bioventus (BVS) Q2 2026 Earnings Call Transcript - The Globe and Mail
Dimensional Fund Advisors LP Increases Position in Bioventus Inc. $BVS - MarketBeat
Bioventus (BVS) Stock Still Looks Like A Bargain On Earnings - Yahoo Finance
The Bull Case For Bioventus (BVS) Could Change Following Its Q2 Earnings Surge And Reaffirmed 2026 Guidance - Yahoo Finance
Bioventus (NASDAQ:BVS) Gains Attention After Strong Quarterly Update - Kalkine Media
Sei Investments Co. Boosts Holdings in Bioventus Inc. $BVS - MarketBeat
Bioventus Inc. (NASDAQ:BVS) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Bioventus (BVS) Is Up 6.1% After Reaffirming 2026 Sales Outlook And Strong Q2 Earnings Jump - Sahm
Bioventus Inc. (BVS) Stock Analysis: Healthcare Innovator With 5.87% Upside Potential - DirectorsTalk Interviews
Bioventus Inc (BVS) Stock News Today - TradingKey
Bioventus Inc (BVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Is Bioventus (BVS) Stock Undervalued Right Now? - Yahoo Finance
Bioventus Inc. $BVS Shares Sold by Renaissance Technologies LLC - MarketBeat
Latham & Watkins Advises Bioventus in Review of Strategic Alternatives - Latham & Watkins LLP
Bioventus Inc (BVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Bioventus Inc 주식 (BVS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| SUTTER MARTIN P | Director |
Jun 02 '26 |
Option Exercise |
0.00 |
32,282 |
0 |
117,523 |
| STALNECKER SUSAN M | Director |
Jun 02 '26 |
Option Exercise |
0.00 |
32,282 |
0 |
138,239 |
| NOHRA GUY P | Director |
Jun 02 '26 |
Option Exercise |
0.00 |
32,282 |
0 |
148,892 |
| NEELS GUIDO J | Director |
Jun 02 '26 |
Option Exercise |
0.00 |
32,282 |
0 |
117,523 |
| McMurry-Heath Michelle | Director |
Jun 02 '26 |
Option Exercise |
0.00 |
32,282 |
0 |
77,279 |
| Ladone Mary Kay | Director |
Jun 02 '26 |
Option Exercise |
0.00 |
32,282 |
0 |
111,263 |
| HAWKINS WILLIAM A | Director |
Jun 02 '26 |
Option Exercise |
0.00 |
39,789 |
0 |
297,640 |
| Cowdy Philip G. | Director |
Jun 02 '26 |
Option Exercise |
0.00 |
32,282 |
0 |
43,982 |
| Beyer Pat | Director |
Jun 02 '26 |
Option Exercise |
0.00 |
32,282 |
0 |
108,718 |
| Singleton Mark Leonard | SVP & CFO |
Apr 10 '26 |
Option Exercise |
0.00 |
13,000 |
0 |
182,981 |
0.26%
0.38%
자본화:
|
볼륨(24시간):